Novel Therapeutic Options in Patients with Type 2 Diabetes and high cardiovascular Risk

被引：0
|
作者：
Laubner, Katharina [1 ]
Seufert, Jochen [2 ]
机构：
[1] Univ Freiburg Klinikum, Klin Innere Med 2, Abt Endokrinol & Diabetol, Freiburg, Germany
[2] Univ Freiburg Klinikum, Klin Innere Med 2, Endokrinol & Diabetol, Freiburg, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2016年 / 141卷 / 11期
关键词：
MELLITUS;
D O I：
10.1055/s-0042-107747
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SGLT2 inhibitors represent a novel therapeutic approach for the tretment of type 2 diabetes mellitus. Beyond glucose control, these drugs also induce weight loss and blod pressure reduction. In a specific cardiovascular outcome trial (EMPA-REG-OUTCOME), the SGLT 2 inhibitor empagliflozin has for the first time demonstrated to reduce cardiovascular and overall mortality as well as hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. These results will drastically affect future recommendations for the treatment of type 2 diabetes mellitus.). © Georg Thieme Verlag KG ·Stuttgart · New York.
引用
收藏
页码：757 / 760
页数：4
相关论文
共 50 条
  • [1] Therapeutic education of patients with Type 2 diabetes mellitus and high cardiovascular risk
    Palfyorova, Ye. A.
    Orlov, V. A.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2007, (06): : 72 - 75
  • [2] Urinary Proteomics in Patients with Type 2 Diabetes at High Cardiovascular Risk
    Currie, Gemma E.
    Friar, Matthew
    Brown, Catriona E.
    Flynn, Joanne
    Mullen, William
    Mischak, Harald
    Delles, Christian
    HYPERTENSION, 2014, 64
  • [3] Cardiovascular risk in patients with type 2 diabetes
    Parmar, M
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (09) : 1160 - 1160
  • [4] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Inzucchi, Silvio E.
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans Juergen
    Broedl, Uli C.
    Zinman, Bernard
    CIRCULATION, 2015, 132 (23) : 2271 - 2271
  • [5] Uncontrolled type 2 diabetes and high cardiovascular risk
    David, Claire
    Boinet, Tomas
    ACTUALITES PHARMACEUTIQUES, 2018, 57 (573): : 14 - 17
  • [6] Current therapeutic options in Type 2 diabetes
    Heine, RJ
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1999, 29 : 17 - 20
  • [7] Optimal Phenomapping Strategy to Identify Novel Subgroups of Patients With Type 2 Diabetes and High Cardiovascular Disease Risk
    Segar, Matthew W.
    Vaduganathan, Muthiah
    Patel, Kershaw V.
    Caughey, Melissa
    Basit, Mujeeb
    Willett, Duwayne
    McGuire, Darren K.
    Pandey, Ambarish
    CIRCULATION, 2020, 141
  • [8] Cardiovascular risk stratification in patients with type 2 diabetes
    Htoo, Phyo Than T.
    Wexler, Deborah
    Glynn, Robert J.
    Schneeweiss, Sebastian
    Paik, Julie M.
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 308 - 309
  • [9] Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes
    Motairek, Issam
    Al-Kindi, Sadeer
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 135 - 147
  • [10] Cardiovascular risk stratification in patients with type 2 diabetes
    Grossmann, V.
    Schmitt, V. H.
    Juenger, C.
    Muenzel, T.
    Wild, P. S.
    DIABETOLOGE, 2014, 10 (07): : 572 - 580
12345